A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis
Read time: 1 mins
Last updated:24th Aug 2012
The primary objectives of the study are: - Superiority of LAS41008 versus placebo based on the proportion of subjects achieving PASI 75 at week 16 (a 75% reduction in the Psoriasis Area and Severity Index, PASI, compared to baseline. - Superiority of LAS41008 versus placebo based on the proportion of subjects achieving a score of �clear� or �almost clear� in the Physician�s Global Assessment (PGA) after 16 weeks of treatment. - Non-inferiority of LAS41008 compared to LASW1835 (internal code for Fumaderm�) regarding PASI 75 after 16 weeks of treatment.
|Study start date||2012-08-24|